These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 17762761)

  • 1. Phase II trial of weekly docetaxel/irinotecan combination in advanced pancreatic cancer.
    Burtness B; Thomas L; Sipples R; McGurk M; Salikooti S; Christoforou M; Mirto G; Salem R; Sosa J; Kloss R; Rahman Z; Chung G; Lacy J; Murren JR
    Cancer J; 2007; 13(4):257-62. PubMed ID: 17762761
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II trial of docetaxel-irinotecan combination in advanced esophageal cancer.
    Burtness B; Gibson M; Egleston B; Mehra R; Thomas L; Sipples R; Quintanilla M; Lacy J; Watkins S; Murren JR; Forastiere AA
    Ann Oncol; 2009 Jul; 20(7):1242-8. PubMed ID: 19429872
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Salvage chemotherapy with mitomycin, docetaxel, and irinotecan (MDI regimen) in metastatic pancreatic adenocarcinoma: a phase I and II trial.
    Reni M; Panucci MG; Passoni P; Bonetto E; Nicoletti R; Ronzoni M; Zerbi A; Staudacher C; Di Carlo V; Villa E
    Cancer Invest; 2004; 22(5):688-96. PubMed ID: 15581049
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase II study of docetaxel-irinotecan combination in advanced pancreatic cancer.
    Kurtz JE; Négrier S; Husseini F; Limacher JM; Borel C; Wagner JP; Prévot G; Bergerat JP; Dufour P
    Hepatogastroenterology; 2003; 50(50):567-70. PubMed ID: 12749274
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized Phase II Trial of Irinotecan/Docetaxel or Irinotecan/Docetaxel Plus Cetuximab for Metastatic Pancreatic Cancer: An Eastern Cooperative Oncology Group Study.
    Burtness B; Powell M; Catalano P; Berlin J; Liles DK; Chapman AE; Mitchell E; Benson AB
    Am J Clin Oncol; 2016 Aug; 39(4):340-5. PubMed ID: 24685886
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase II study of irinotecan and docetaxel combination chemotherapy for patients with previously treated metastatic or recurrent advanced gastric cancer.
    Sym SJ; Chang HM; Kang HJ; Lee SS; Ryu MH; Lee JL; Kim TW; Yook JH; Oh ST; Kim BS; Kang YK
    Cancer Chemother Pharmacol; 2008 Dec; 63(1):1-8. PubMed ID: 18288477
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer: CALGB 89904.
    Kulke MH; Tempero MA; Niedzwiecki D; Hollis DR; Kindler HL; Cusnir M; Enzinger PC; Gorsch SM; Goldberg RM; Mayer RJ
    J Clin Oncol; 2009 Nov; 27(33):5506-12. PubMed ID: 19858396
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II study of docetaxel and irinotecan in metastatic or recurrent esophageal cancer: a preliminary report.
    Govindan R; Read W; Faust J; Trinkaus K; Ma MK; Baker SD; McLeod HL; Perry MC
    Oncology (Williston Park); 2003 Sep; 17(9 Suppl 8):27-31. PubMed ID: 14569845
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II study with fractionated schedule of docetaxel and cisplatin in patients with advanced non-small cell lung cancer.
    Kwon JH; Kim JH; Lee JA; Shin HC; Kim HJ; Song HH; Jung JY; Kim HY; Choi DR; Kim HS; Park YI; Zang DY
    Cancer Chemother Pharmacol; 2010 Oct; 66(5):889-97. PubMed ID: 20091311
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase I/II trial of fixed-dose docetaxel plus irinotecan and escalating doses of estramustine phosphate for second-line or greater treatment of selected advanced solid tumors.
    Baz W; Nakhl F; El-Soueidi R; Forte F; Lowry J; Aoun N; Burton J
    Anticancer Drugs; 2009 Jul; 20(6):508-12. PubMed ID: 19318913
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Second-line chemotherapy with capecitabine (Xeloda) and docetaxel (Taxotere) in previously treated, unresectable adenocarcinoma of pancreas: the final results of a phase II trial.
    Katopodis O; Polyzos A; Kentepozidis N; Giassas S; Rovithi M; Bozionelou V; Kalbakis K; Vamvakas L; Mavroudis D; Georgoulias V
    Cancer Chemother Pharmacol; 2011 Feb; 67(2):361-8. PubMed ID: 20428874
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II study of cisplatin combined to irinotecan administered alternatingly with docetaxel in advanced non-small cell lung cancer.
    Charoentum C; Thongprasert S; Chewasakulyong B; Euathrongchit J; Sorraritchingchai S; Munprakan S
    J Med Assoc Thai; 2007 Nov; 90(11):2506-12. PubMed ID: 18181342
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Excess toxicity associated with docetaxel and irinotecan in patients with metastatic, gemcitabine-refractory pancreatic cancer: results of a phase II study.
    Ko AH; Dito E; Schillinger B; Venook AP; Bergsland EK; Tempero MA
    Cancer Invest; 2008 Feb; 26(1):47-52. PubMed ID: 18181045
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II study of docetaxel and cisplatin combination chemotherapy in metastatic gastric cancer.
    Park KW; Ahn JS; Park YS; Lee J; Kang JH; Park JO; Lim HY; Im YH; Kang WK; Park K; Lee SI
    Cancer Chemother Pharmacol; 2007 Jan; 59(1):17-21. PubMed ID: 16721549
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Irinotecan, oxaliplatin, and 5-fluorouracil/leucovorin combination chemotherapy in advanced colorectal carcinoma: a phase II study.
    Calvo E; Cortés J; Rodríguez J; Fernández-Hidalgo O; Rebollo J; Martín-Algarra S; García-Foncillas J; Martínez-Monge R; de Irala J; Brugarolas A
    Clin Colorectal Cancer; 2002 Aug; 2(2):104-10. PubMed ID: 12453325
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Docetaxel/cisplatin followed by FOLFIRI versus the reverse sequence in metastatic gastric cancer.
    Kim JA; Lee J; Han B; Park SH; Park JO; Park YS; Lim HY; Kang WK
    Cancer Chemother Pharmacol; 2011 Jul; 68(1):177-84. PubMed ID: 20878159
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Two different schedules of irinotecan (CPT-11) in patients with advanced colorectal carcinoma relapsing after a 5-fluorouracil and leucovorin combination. A randomized study.
    Tsavaris N; Ziras N; Kosmas C; Giannakakis T; Gouveris P; Vadiaka M; Dimitrakopoulos A; Karadima D; Rokana S; Papalambros E; Papastratis G; Margaris H; Tsipras H; Polyzos A
    Cancer Chemother Pharmacol; 2003 Dec; 52(6):514-9. PubMed ID: 14504920
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II study of biweekly administration of docetaxel and irinotecan in patients with refractory or relapsed advanced non-small cell lung cancer.
    Hirose T; Shirai T; Ishida H; Ando K; Sugiyama T; Kusumoto S; Hosaka T; Nakashima M; Ohmori T; Adachi M
    Cancer Chemother Pharmacol; 2007 Jul; 60(2):267-74. PubMed ID: 17273827
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Irinotecan plus oxaliplatin and leucovorin-modulated fluorouracil in advanced pancreatic cancer--a Groupe Tumeurs Digestives of the Federation Nationale des Centres de Lutte Contre le Cancer study.
    Conroy T; Paillot B; François E; Bugat R; Jacob JH; Stein U; Nasca S; Metges JP; Rixe O; Michel P; Magherini E; Hua A; Deplanque G
    J Clin Oncol; 2005 Feb; 23(6):1228-36. PubMed ID: 15718320
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Weekly docetaxel, cisplatin, and irinotecan (TPC): results of a multicenter phase II trial in patients with metastatic esophagogastric cancer.
    Enzinger PC; Ryan DP; Clark JW; Muzikansky A; Earle CC; Kulke MH; Meyerhardt JA; Blaszkowsky LS; Zhu AX; Fidias P; Vincitore MM; Mayer RJ; Fuchs CS
    Ann Oncol; 2009 Mar; 20(3):475-80. PubMed ID: 19139178
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.